Healthcare / Medical DevicesNasdaqGS
$1.15
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-82.6M · quality 71.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
29/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$449M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-17.7%
↓Gross Margin
49.9%
↑Debt/Equity
0.07
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+7.9%
FCF CAGR
—
FCF margin
-96.9%
FCF / Net income
1.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $85.3M · net income $-74.9M · FCF $-82.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $85.3M | $85.3M | $91.0M | $106.3M | $97.9M | $130.6M | $138.1M | $117.2M | $113.0M | $101.9M | $104.4M | $114.7M | $116.5M | $71.2M | $52.3M | $42.9M | $33.6M | $25.4M |
| Net Income | $-74.9M | $-74.9M | $-138.9M | $-74.7M | $-190.1M | $-59.2M | $-53.0M | $-64.8M | $-59.0M | $-60.5M | $-76.0M | $-53.3M | $-52.8M | $-16.5M | $-19.0M | $-22.5M | $-16.9M | $-19.1M |
| EBITDA | $-85.7M | $-85.7M | $-70.2M | $-54.5M | $-173.6M | $-64.2M | $-47.0M | $-47.2M | $-42.8M | $-51.0M | $-66.5M | $-45.2M | $-47.8M | $-16.1M | $-15.9M | $-17.2M | $-13.4M | $-16.4M |
| EPS | -0.20 | -0.20 | -0.52 | -0.94 | -2.43 | -0.78 | -0.74 | -0.97 | — | — | — | — | — | — | — | — | — | — |
| Gross Margin | 49.9% | 49.9% | 49.3% | 47.4% | 37.8% | — | — | 54.8% | 54.6% | 51.0% | 55.9% | — | — | — | — | — | — | — |
| Operating Margin | -109.3% | -109.3% | -95.6% | -59.3% | -104.8% | -51.7% | -36.9% | -44.2% | -42.6% | -57.3% | -70.1% | -43.7% | -44.5% | -26.2% | -34.5% | -43.3% | -43.4% | -71.0% |
| Net Margin | -87.8% | -87.8% | -152.6% | -70.2% | -194.1% | -45.4% | -38.4% | -55.3% | -52.2% | -59.4% | -72.8% | -46.5% | -45.4% | -23.2% | -36.4% | -52.4% | -50.4% | -75.3% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.07 | 0.07 | 0.07 | -0.66 | -1.26 | — | — | — | — | — | — | — | — | — | 0.00 | 0.02 | -0.05 | — |
| Current Ratio | 12.36 | 12.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-82.6M | $-82.6M | $-151.8M | $-46.1M | $-93.2M | $-57.3M | $-28.1M | $-37.7M | $-25.6M | $-25.7M | $-44.2M | $-38.7M | $-30.0M | $-5.0M | $-19.9M | $-19.2M | $-13.0M | $-20.3M |
| Returns | ||||||||||||||||||
| ROE | -17.7% | -17.7% | -29.4% | 50.4% | 233.3% | -62.6% | -38.1% | -42.2% | -81.8% | -195.7% | -142.7% | -46.4% | -35.1% | -17.1% | -18.9% | -39.5% | 8.9% | 11.0% |
| Valuation | ||||||||||||||||||
| P/B | 1.03 | 1.03 | 1.36 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | -6.2% | -6.2% | -14.4% | 8.6% | — | -5.5% | 17.8% | 3.8% | 10.8% | -2.4% | -8.9% | -1.5% | 63.6% | 36.0% | 22.1% | 27.7% | 32.1% | — |
| EPS Growth | 61.5% | 61.5% | 44.7% | 61.3% | — | -5.4% | 23.7% | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+13.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.52 → -0.20
Residual
+13.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.